Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 11 for:    pelvic pain AND NICHD

Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03124160
Recruitment Status : Active, not recruiting
First Posted : April 21, 2017
Last Update Posted : July 9, 2021
Sponsor:
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
FHI 360
Information provided by (Responsible Party):
Health Decisions

Tracking Information
First Submitted Date  ICMJE February 9, 2017
First Posted Date  ICMJE April 21, 2017
Last Update Posted Date July 9, 2021
Actual Study Start Date  ICMJE May 26, 2017
Estimated Primary Completion Date May 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 18, 2017)
Pregnancy Rate [ Time Frame: 3 years ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 26, 2017)
  • IUD continuation at months 12, 24 and 36 as measured by confirmation of IUD placement (visible or palpable) [ Time Frame: 3 years ]
  • Failed IUD insertion as measured by inability to place the IUD correctly [ Time Frame: 3 years ]
  • Uterine perforation as measured by ultrasound [ Time Frame: 3 years ]
  • IUD expulsion (complete and partial) [ Time Frame: 3 years ]
  • Vaginal bleeding patterns [ Time Frame: 3 years ]
  • Pelvic pain as measured in the subject diary [ Time Frame: 3 years ]
  • Dysmenorrhea [ Time Frame: 3 years ]
  • Other side effects as measured by adverse and/or other events [ Time Frame: 3 years ]
  • Pain with and shortly after insertion as measured by visual analog scale completed by study subjects [ Time Frame: 3 years ]
  • Ease of IUD insertion as measured by asking the investigator to assess ease of insertion [ Time Frame: 3 years ]
  • Overall product satisfaction as measured by acceptability questions asked of subjects [ Time Frame: 3 years ]
Original Secondary Outcome Measures  ICMJE
 (submitted: April 18, 2017)
  • IUD continuation at months 12, 24 and 36 as measured by Confirmation of IUD placement (visible or palpable) [ Time Frame: 3 years ]
  • Failed IUD insertion as measured by lack of proper insertion and subject discontinuations from the study [ Time Frame: 3 years ]
  • Uterine perforation as measured by ultrasound and subject discontinuations from the study [ Time Frame: 3 years ]
  • IUD expulsion (complete and partial) [ Time Frame: 3 years ]
  • Vaginal bleeding patterns [ Time Frame: 3 years ]
  • Pelvic pain as measured in the subject diary [ Time Frame: 3 years ]
  • Dysmenorrhea [ Time Frame: 3 years ]
  • Other side effects as measured by adverse and/or other events [ Time Frame: 3 years ]
  • Pain with and shortly after insertion as measured by visual analog scale completed by study subjects [ Time Frame: 3 years ]
  • Ease of IUD insertion as measured by asking the investigator to assess ease of insertion [ Time Frame: 3 years ]
  • Overall product satisfaction as measured by acceptability questions asked of subjects [ Time Frame: 3 years ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard
Official Title  ICMJE A Multi-center, Single-blind, Randomized Clinical Trial to Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard
Brief Summary This will be a multi-site, participant-blinded, randomized clinical trial. The investigators will randomize 1000 eligible participants in a 4:1 ratio to two different copper IUDs: 800 to Mona Lisa NT Cu380 Mini and 200 to ParaGard.
Detailed Description

The total duration of the study for each participant is expected to be approximately 39 months: including screening and enrollment (up to 30 days to meet enrollment criteria), 37 months of participation, and a post-removal follow up telephone call 17 days post-removal. After enrollment, subject visits occur at 6 weeks, 3 months, 6 months, 12 months, 24 months, with telephone calls at 9, 18, and 30 months and seen again at 37 months for their final visit. Subjects will use a home pregnancy test 17 days post-removal of the IUD or Exit Visit procedures, whichever occurs first, and called by the site for the result and for safety follow-up.

Subject recruitment is expected to begin Q2 (in the second quarter of) 2017 and is planned to continue through Q2 2018. However, if the enrollment rate declines, the enrollment period may be extended beyond this date. If this enrollment timeline is met, all subjects should finish active treatment by approximately the end of Q2 2021. The total duration of the study will be approximately 48 months for each study site including pre- and post- trial activities. The end of the study will occur when the last subject to be enrolled has completed her post-removal pregnancy test telephone call.

Total duration of the project is expected to be five years. Preliminary results of the study are expected to be available Q4 of 2019 based on the current study plan.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Other
Condition  ICMJE
  • Healthy Women
  • Female Contraception
Intervention  ICMJE
  • Drug: Mona Lisa® NT Cu380 Mini
    Mona Lisa® NT Cu380 Mini
  • Drug: ParaGard® CuT380A
    ParaGard® CuT380A
Study Arms  ICMJE
  • Experimental: Mona Lisa® NT Cu380 Mini
    Mona Lisa® NT Cu380 Mini containing 380mm2 of copper surface inserted into the uterine cavity.
    Intervention: Drug: Mona Lisa® NT Cu380 Mini
  • Active Comparator: ParaGard® CuT380A
    ParaGard® CuT380A containing 380mm2 of copper surface inserted into the uterine cavity.
    Intervention: Drug: ParaGard® CuT380A
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: June 1, 2017)
1000
Original Estimated Enrollment  ICMJE
 (submitted: April 18, 2017)
600
Estimated Study Completion Date  ICMJE November 1, 2022
Estimated Primary Completion Date May 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • 16-40 years

    o 16 and 17 year olds, where permissible by state regulations and local Institutional Review Board (IRB) approval

  • Sexually active, anticipating at least one act of vaginal intercourse per menstrual cycle with a male partner and at risk for pregnancy
  • seeking contraception, and willing to use the study IUD as the only contraception method
  • willing to be randomized to one of the two copper IUDs
  • has an intact uterus and at least one ovary
  • has a history of regular menstrual cycles; defined as occurring every 21-35 days when not using hormones, and with a variation of typical cycle length of no more than 5 days
  • able and willing to provide written informed consent
  • agrees to follow all study requirements
  • not currently pregnant or at risk for luteal phase pregnancy based on history of unprotected intercourse

Exclusion Criteria:

  • abnormal Pap requiring treatment after enrollment
  • known human immunodeficiency virus / acquired immunodeficiency syndrome (HIV/AIDS) infection
  • intending to become pregnant in the 37 months after enrollment
  • known infertility
  • history of allergy or sensitivity to copper
  • previous tubal sterilization
  • has received an injectable contraceptive in the last 9 months and has not resumed regular menstrual cycles (as evidenced by 2 spontaneous menses)
  • within 30 days of administration of mifepristone and/or misoprostol for medical abortion or for miscarriage management
  • within 30 days of first, second, or third trimester abortion or miscarriage (note: potential abortion/miscarriage participants can be screened and return after 30 days for randomization and IUD insertion)
  • within 30 days of delivery (for parous population)
  • breastfeeding or recently breastfeeding women unless two consecutive normal menstrual periods have occurred after delivery and prior to enrollment.
  • wants to use a copper IUD for emergency contraception
  • has previously participated in the study
  • participated in another clinical trial involving an investigational product within the last 30 days (before screening) or planning to participate in another clinical trial involving an intervention or treatment during this study
  • not living in the catchment area of the study site or planning to move from the area within the year (unless known to be moving to the catchment area of another study site)
  • known or suspected current alcohol or drug abuse
  • planning to undergo major surgery during study participation
  • current need for use of exogenous hormones or therapeutic anticoagulants (Note: subjects who start a therapeutic anticoagulant after enrolment will be allowed to continue in the study.)
  • at high risk for sexually-transmitted infections or pelvic infection
  • anticipated need for regular condom use (refer to Section 8.1).
  • has any condition (social or medical) which in the opinion of the Investigator would make study participation unsafe or complicate data interpretation
  • Reported medical contraindications (Medical Eligibility Criteria category 3 or 4)14 to copper IUDs, including:

    • suspicious unexplained vaginal bleeding
    • known cervical cancer
    • known endometrial cancer
    • known Wilson's disease
    • Confirmed gestational trophoblastic disease with persistently elevated beta-hCG levels or malignant disease, with evidence or suspicion of intrauterine disease
    • anatomic abnormalities with distorted uterine cavity
    • current pelvic inflammatory disease (PID)
    • pelvic tuberculosis
    • immediately post-septic abortion or puerperal sepsis
    • current known purulent cervicitis or chlamydial infection or gonorrhea; Note: to enroll, there must be no obvious signs of infection at the time of enrollment based on pelvic exam. If lab results come back for positive infection after enrollment, treatment should be provided but the IUD can be left in place.
    • complicated solid organ transplantation
    • systemic lupus erythematosus with severe thrombocytopenia
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 16 Years to 40 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03124160
Other Study ID Numbers  ICMJE CCN016
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Health Decisions
Study Sponsor  ICMJE Health Decisions
Collaborators  ICMJE
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • FHI 360
Investigators  ICMJE
Study Director: Diana Blithe National Institute of Child Health & Human Development (NICHD)
Study Director: David Hubacher FHI 360
PRS Account Health Decisions
Verification Date July 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP